- $27.40m
- $14.11m
- $48.87m
Annual income statement for Bioqual, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | 2026 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Preliminary |
| Revenue | |||||
| Total Revenue | 66.2 | 62.7 | 58.6 | 48.9 | 39.9 |
| Cost of Revenue | |||||
| Gross Profit | 13 | 8.64 | 7.43 | 4.42 | — |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 59.6 | 61.6 | 58.6 | 50.8 | — |
| Operating Profit | 6.53 | 1.1 | -0.02 | -1.9 | — |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 6.58 | 1.13 | 0.476 | -1.29 | -3.72 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5.26 | 0.836 | 0.483 | -1.05 | — |
| Net Income Before Extraordinary Items | |||||
| Net Income | 5.26 | 0.836 | 0.483 | -1.05 | — |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5.26 | 0.836 | 0.483 | -1.05 | — |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5.88 | 0.934 | 0.541 | -1.17 | — |
| Dividends per Share |